Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Income from Continuing Operations (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of Income from Continuing Operations data on record, last reported at 19503000.0 in Q4 2024.

  • For Q4 2024, Income from Continuing Operations rose 19.09% year-over-year to 19503000.0; the TTM value through Dec 2024 reached 86620000.0, up 11.99%, while the annual FY2024 figure was 86620000.0, 11.99% up from the prior year.
  • Income from Continuing Operations reached 19503000.0 in Q4 2024 per FHTX's latest filing, down from 19122000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13982000.0 in Q1 2020 and bottomed at 30488000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 23303900.0, with a median of 23931000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: tumbled 68.9% in 2021, then surged 44.33% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 21100000.0 in 2020, then crashed by 35.11% to 28508000.0 in 2021, then fell by 1.33% to 28886000.0 in 2022, then grew by 16.55% to 24106000.0 in 2023, then rose by 19.09% to 19503000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 19503000.0 in Q4 2024, 19122000.0 in Q3 2024, and 22979000.0 in Q2 2024.